My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
From Brodsky & Smith LLC
Via GlobeNewswire
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play
Via Stocktwits
BioCryst To Acquire Astria Therapeutics In $700M Deal
Via Stocktwits
This Verisk Analytics Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit revenue growth. 
Via Benzinga
Which stocks are gapping on Tuesday?
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Inc (NASDAQ:ATXS) Reports Narrower-Than-Expected Q2 2025 Loss and Strong Cash Runway
Astria Therapeutics reports Q2 2025 results with a narrower-than-expected loss, extended cash runway, and progress in clinical trials for navenibart and STAR-0310. 
Via Chartmill
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
From Astria Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.